Scorr-Insert
X

Find Neurology Drugs in Phase II Clinical Development in UNITED STATES

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ANVS401

            Therapeutic Area: Neurology

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 30, 2020

            Details:

            Annovis Bio plans to proceed with a two-part study designed to treat a combined total of 68 Alzheimer’s and Parkinson’s patients for one month with Annovis’ compound, ANVS401.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Sodium 4-Phenylbutyrate,Tauroursodeoxycholic Acid

            Therapeutic Area: Neurology

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 29, 2020

            Details:

            In late 2019, Amylyx announced that the CENTAUR clinical trial of AMX0035 in patients with ALS met its primary endpoint, demonstrating statistically significant, longer retention of function.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PTI-125

            Therapeutic Area: Neurology

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: National Institutes of Health

            Deal Size: $2.5 million Upfront Cash: Undisclosed

            Deal Type: Funding April 23, 2020

            Details:

            Grant will support an on-going clinical evaluation of lead investigational drug PTI-125 in alzheimer’s disease.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): NB-01

            Therapeutic Area: Neurology

            Highest Development Status: Phase II Product Type: Undisclosed

            Partner/Sponsor/Collaborator: H.C. Wainwright

            Deal Size: $7.5 million Upfront Cash: Undisclosed

            Deal Type: Public Offering April 16, 2020

            Details:

            The Company intends to use the net proceeds from this offering for working capital, capital expenditures and general corporate purposes.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CVN424

            Therapeutic Area: Neurology

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Google Ventures

            Deal Size: $45.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing April 14, 2020

            Details:

            The proceeds will advance the company's lead Parkinson's disease plan into phase 2 and move other prospects into the clinic from earlier stages.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): NSI-566

            Therapeutic Area: Neurology

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 09, 2020

            Details:

            As a result of the discussion and feedback received from the FDA, Seneca believes that the existing phase 1 and 2 trial results support moving into a phase 3 clinical study for ALS.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): NSI-566

            Therapeutic Area: Neurology

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 07, 2020

            Details:

            As of now follow-up assessments had been completed on 60% of the subjects in the trial and the company continues to expect data readout to be available during the second half of 2020.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Pepinemab

            Therapeutic Area: Neurology

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 07, 2020

            Details:

            Presentation highlighted the potential of the company’s lead candidate, pepinemab, to regulate glial cell activation and neurodegeneration in Alzheimer’s and Huntington’s disease.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): VY-AADC

            Therapeutic Area: Neurology

            Highest Development Status: Phase II Product Type: Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 03, 2020

            Details:

            Voyager and Neurocrine Biosciences have temporarily paused screening of new patients in the RESTORE-1 trial to allow clinical trial sites to assess the impact of the COVID-19 pandemic.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Pepinemab

            Therapeutic Area: Neurology

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Keystone Capital Partners

            Deal Size: $16.5 million Upfront Cash: Undisclosed

            Deal Type: Financing March 31, 2020

            Details:

            Company has entered into two agreements offering considerable financial stability for Vaccinex that will enhance the development of its lead therapeutic product, pepinemab.

            PharmaCompass